PHARMACYTE BIOTECH, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
PHARMACYTE BIOTECH, INC. (PMCB) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $4.15 million for the 12-month period ending 2026-04-30, per its 10-K filed 2026-07-29.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-07-29
- PHARMACYTE BIOTECH, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2026 was $4.15M, a 14707.81% increase from fiscal 2025.
- PHARMACYTE BIOTECH, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $28.00K.
- PHARMACYTE BIOTECH, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $470.94K.
- PHARMACYTE BIOTECH, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was -$739.80K, a 176.33% decline from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2026-04-30 | $4.15M 10-K · filed 2026-07-29 |
| 2025-04-30 | $28.00K 10-K · filed 2026-07-29 |
| 2023-04-30 | $470.94K 10-K · filed 2023-07-31 |
| 2022-04-30 | -$739.80K 10-K · filed 2023-07-31 |
| 2021-04-30 | $969.24K 10-K · filed 2022-07-28 |
| 2020-04-30 | $1.34M 10-K · filed 2021-08-10 |
| 2019-04-30 | $952.17K 10-K · filed 2020-08-13 |
| 2013-04-30 | $256.69K 10-K · filed 2013-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |